Alex Goldberg

PACCAR Inc. (NASDAQ:PCAR) and PDL BioPharma, Inc. (NASDAQ:PDLI) Added to Equity Profile Report's NASDAQ Gainers Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 02/07/2014 -- Equity Profile Report expands its NASDAQ Gainers Weekly Watch List adding PACCAR Inc. (NASDAQ:PCAR) and PDL BioPharma, Inc. (NASDAQ:PDLI).

PACCAR Inc. (NASDAQ:PCAR) a company that together with its subsidiaries, designs, manufactures, and distributes light, medium, and heavy-duty trucks and related aftermarket parts worldwide is currently up (+0.58%) on 1,497,179 shares traded after PACCAR INC Reported its Financials. PACCAR Inc. (NASDAQ:PCAR) is currently up (+30.06%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List.

Click Here to find out what other Investors are saying about PACCAR Inc. (NASDAQ:PCAR)

PDL BioPharma, Inc. (NASDAQ:PDLI) a company that engages in intellectual property asset management and patent portfolio and related assets investment activities is currently up (+3.70%) on 5,237,972 shares traded after PDL BioPharma Priced Offering of $260.87 Million of Convertible Senior Notes Due 2018. PDL BioPharma, Inc. (NASDAQ:PDLI) is currently up (+22.73%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List.

Click Here to find out what other Investors are saying about PDL BioPharma, Inc. (NASDAQ:PDLI)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com